EPA-FFA to Treat Hospitalised Patients With COVID-19 (SARS-CoV-2)
NCT04335032 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 284
Last updated 2021-12-03
Summary
This is an double-blind, randomized, placebo controlled phase III study in hospitalized subjects with confirmed SARS-CoV-2.
Conditions
Interventions
- DRUG
-
Eicosapentaenoic acid gastro-resistant capsules
same as in arm/group description
- DRUG
-
same as in arm/group description
Sponsors & Collaborators
-
S.L.A. Pharma AG
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-01-08
- Primary Completion
- 2021-11-30
- Completion
- 2021-12-01
Countries
- Spain
- United Kingdom
Study Locations
More Related Trials
-
Eicosapentaenoic Acid (EPA) for Treatment of Colorectal Cancer Liver Metastases
NCT01070355 ·Status: COMPLETED ·Phase: PHASE2
-
The Effect of Omega-3 on Selected Cytokines Involved in Cytokine Storm
NCT04483271 ·Status: COMPLETED ·Phase: NA
-
Eicosapentaenoic Acid (EPA)and Docosahexaenoic Acid Study
NCT01400490 ·Status: UNKNOWN ·Phase: NA
-
The Efficacy of EPA+DHA (SC401B) for Lowering Triglyceride Levels (≥ 500 mg/dL)
NCT01997268 ·Status: WITHDRAWN ·Phase: PHASE3
-
Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia
NCT01350999 ·Status: COMPLETED ·Phase: PHASE3
-
Fenofibrate and Omega-3 Fatty Acid Modulation of Endotoxemia
NCT01048502 ·Status: COMPLETED ·Phase: NA
-
A Study in Healthy Subjects to Compare the Bioavailability of EPA + DHA
NCT06629103 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Effects of a Prescription Omega-3 Fatty Acid Concentrate on Induced Inflammation
NCT01813110 ·Status: COMPLETED ·Phase: NA
-
Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia
NCT04177680 ·Status: COMPLETED ·Phase: PHASE2
-
Explore Effects of Dietary Fish Oil in Human Skin
NCT03122912 ·Status: TERMINATED ·Phase: PHASE1
-
The Impact of Fish-oil Fatty Acids on Postprandial Vascular Reactivity
NCT01692431 ·Status: COMPLETED ·Phase: NA
-
Differential Thrombogenesis by EPA and DHA Mediated by HDL
NCT06494488 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Investigating the Effect of 4-week Omega-3 Polyunsaturated Fatty Acid Supplementation on Inflammation
NCT03210805 ·Status: UNKNOWN ·Phase: NA
-
An Efficacy and Safety Study of Omega-3-acid Ethyl Ester in Chinese Subjects With Hypertriglyceridemia.
NCT04756180 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study to Assess High-DHA Fish Oil on Biomarkers of Cardiovascular Disease Risk in Adults on Statin Therapy
NCT01690312 ·Status: COMPLETED ·Phase: NA
-
Study of the Efficacy and Safety of EPA in Patients With Type-2 Diabetes
NCT06129526 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Evaluation of the Safety and Efficacy of Long-term Use of Omega-3 Fatty Acid Ethyl Esters
NCT02153073 ·Status: COMPLETED
-
Efficacy of TAK-085 in Participants With Hypertriglyceridemia
NCT01350973 ·Status: COMPLETED ·Phase: PHASE3
-
Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels
NCT00578578 ·Status: TERMINATED ·Phase: PHASE4
-
Comparative Study of Three Different Formulations of Omega-3 (EPA+DHA)
NCT04159532 ·Status: COMPLETED ·Phase: PHASE4
-
Fish Oils and Adipose Inflammation Reduction
NCT02010359 ·Status: COMPLETED ·Phase: PHASE4
-
Postprandial Lipid Metabolism in Familial Hypercholesterolaemia:Effects of Fish Oils
NCT01577056 ·Status: UNKNOWN ·Phase: NA
-
Cardiometabolic Properties of Omega-3 Functionalized With Hydroxytyrosol
NCT06992323 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
A Study to Evaluate the Effect of Fish Oil Concentrate on Skin Function
NCT07133477 ·Status: RECRUITING ·Phase: NA
-
The Effects of Omega-3 Fatty Acids on Aspirin Resistance
NCT00771914 ·Status: COMPLETED ·Phase: PHASE1/PHASE2